The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II multicenter study of second-line FOLFIRI plus cetuximab (FLIER) in patients with KRAS wild-type metastatic colorectal cancer: Final analysis of survival and additional analysis of BRAF, PI3CA mutations.
Yasuhiro Miyake
No relevant relationships to disclose
Shigeyoshi Iwamoto
No relevant relationships to disclose
Shoichi Hazama
No relevant relationships to disclose
Fuminori Goda
No relevant relationships to disclose
Chu Matsuda
No relevant relationships to disclose
Kenji Amagai
No relevant relationships to disclose
HIroyuki Bandou
No relevant relationships to disclose
Mutsumi Fukunaga
No relevant relationships to disclose
Naoki Nagata
No relevant relationships to disclose
Junichi Sakamoto
No relevant relationships to disclose
Hideyuki Mishima
No relevant relationships to disclose